Quote from admin on July 27, 2021, 9:00 pmIn this episode we are explore how a conscientious doctor turned from blindly believing in vaccines to looking at the actual science, challenging her beliefs and coming out as a strong science-based, pro choice advocate for medical freedom.
If you are wondering why doctors are not speaking up in the current situation, Dr. Jayne Donegan's story might shed some light on the underlying reasons.
In this episode we are explore how a conscientious doctor turned from blindly believing in vaccines to looking at the actual science, challenging her beliefs and coming out as a strong science-based, pro choice advocate for medical freedom.
If you are wondering why doctors are not speaking up in the current situation, Dr. Jayne Donegan's story might shed some light on the underlying reasons.
[vc_row][vc_column][vc_column_text]
[/vc_column_text][/vc_column][/vc_row]
Dr. Sherri J. Tenpenny is an osteopathic medical doctor, board certified in three medical specialties. She is the most outspoken physician on the adverse impact that vaccines can have on health. She has lectured at Cleveland State University and Case Western Reserve Medical School, and has been a speaker at conventions, both nationally and internationally, as a recognised expert on a wide range topics within the field of Integrative Medicine including breast health, breast thermography, women’s hormones, medical uses of iodine and the adverse effects vaccines have on health.
BA in Chemistry from University of Virginia in 1980 and a PhD in biochemistry and molecular biology from George Washington University in 1992. Judy has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development. in 1999, when she directed the Laboratory of Antiviral Drug Mechanisms in developing therapeutics and diagnostics for HIV/AIDS and AIDS associated malignancies. In 2014 she and Kent Heckenlively co-authored the book Plague.
Research and innovation areas are proteomics, protein arrays, biomarker discovery and validation. She co-founded a Max-Planck-Institute, Berlin spin-out, Protagen AG, a successful German biomedical company (1997-2019) (www.protagen.de). She has advised on Science and Innovation as a Member of Ireland?s Advisory Science Council (2005-2014); as European Commission Seconded National Expert (2013-2014) and as a Member of the EU Innovative Medicines Initiative Scientific Committee (2016-2021) and as Vice-Chair of this IMI Scientific Committee (2018-2021).
Co-Founder and Chair of International Small Business Alliance [ISBA], Joint Chair of Public Banking Forum of Ireland [PBFI], long-time member of Transparency International Ireland and Right2Homes and is also a member of the Stop CETA Alliance. In 2019, he was appointed as advisor to Independent Farmers of Ireland [IFoI]. He was Competition Consultant to the British Aggregates Association for 18 years and has worked internationally on Antitrust / Competition related matters.
Batchelor of Sciences honours degree (applied social sciences) , and a PhD including a 4-year research study of public health care organisational culture and change. Finbar has worked as a social care practitioner, healthcare trainer, and third level educator. Finbar has also spent ten years as an activist with his activism focused mainly against economic evictions by financial institutions Finbar is also Primary Carer for his 86 year old mother with a number of underlying conditions that make her susceptible to COVID19.
Research director of www.GoldCore.com�which he founded in 2003. GoldCore are international gold brokers and have over 16,000 clients in over 140 countries, sales of over $1.1 billion and with over $130 million in bullion assets under management & storage. Specialties include: Provision of Precious Metals in Safest Ways Possible, Financial, Economic and Monetary Research and Analysis, Analysis of the Precious Metal and Wider Markets, Evaluation of Macroeconomic, Geopolitical and Systemic Risk.
